Melatonin ReceptorBased Antidepressant Therapy in USA

From Human's Love
Jump to: navigation, search

Self-medication is not the way that is best of dealing with a severe form of depression. Various psychoactive natural compounds are typically used in this practice that is potentially harmful. antidepressants bipolar from alcohol to products that are over-the-counter the hormone melatonin. Hormonal therapies are best suited for the replacement of pathologically low or missing levels of endogenous hormones; using insulin to treat diabetes is a example that is good. It is hard to create a simple and case that is convincing the use of melatonin replacement therapy - too many miracle cures have already been associated with melatonin. Possibly the best use of this hormone should be to regulate rest patterns or to prevent jet lag. But could melatonin be therapeutic for conditions such as for instance severe depression? No medical data are available to support that is conclusively usage of melatonin in antidepressant therapy. However, clinical results declare that melatonin receptors may be involved.

a search for clinical studies with melatonin in the U.S. Government-sponsored database called on June 7, 2011 revealed 128 studies. of these trials have been designed to explore the effects of melatonin supplementation on sleep. None of them investigated melatonin supplementation in the treatment of depression. One study measured melatonin levels in the blood of patients with major disorder that is depressive and a few studies investigated the consequences of light therapy in depression and measured melatonin levels in treated subjects. This really is in a stark contrast to the amount of clinical trials with a drug that stimulates melatonin receptors, a target considered to be specific for the cellular activities of melatonin. The compound in case, agomelatine, has been authorized in European countries for treatment of depression and is now being investigated within the U.S.
How would melatonin receptors work to reduce apparent symptoms of serious depression? Imagine for a moment you've simply won a Mega that is huge millions and you've bought yourself a mansion. It's a castle that is huge a lot of doorways, each with at least one lock and some with several. These locks are the melatonin receptors. There are depression bipolar support alliance of these receptors, MT1 and MT2. You've also got the master key, melatonin, which opens both types of locks. To the in-laws who poured in to visit as soon as they'd heard of your fortune you only give keys to certain locks, the MT1 or the MT2, so you can keep some privacy. For the special room in which you keep your most valued possessions, you have an additional layer of security, a door equipped not only with both MT1 and MT2 locks, but also with an unusual lock, the serotonin receptor called 5-HT2C. To open this door, the 5-HT2C lock must be locked at the same time you are using the master key to unlock the MT1 and MT2 locks. Quite a job!
Evidently, you certainly can do the identical to your brain 5-HT2C, MT1, and MT2 receptors by taking agomelatine, a drug that acts simultaneously on the MT1 and MT2 melatonin receptors (as their agonist) and on the serotonin that is 5-HT2C (as their antagonist). Scientists believed that this simultaneous manipulation of brain melatonin and 5-HT2C serotonin receptors decreases the outward symptoms of major depression. Based on in Malaga depression rates in america , using melatonin only would maybe not produce the effect that is same.
In their article The Pattern of Melatonin Receptor Expression in the Brain may Influence Antidepressant Treatment, Dr. Eric Hirsch-Rodriguez and colleagues from the Department of Psychiatry at the University of Illinois at Chicago described how the presence of melatonin receptors such as MT1 and MT2 in different brain areas changes over time and can be affected by illness and drug treatment. For example, prolonged treatment with classical antidepressants changes the content of the MT1 and MT receptors. These investigators suggested that melatonin or drugs based on melatonin would produce antidepressant effects only if an optimal amount and brain distribution of melatonin receptors are offered for medication action and that clinical trials with such drugs would need to take into consideration the characterization of patients' melatonin receptors.
Agomelatine, the melatonin that is first antidepressant, is currently being clinically evaluated for approval for use in U.S. On June 7, 2011, listed 9 clinical trials (one has been withdrawn) with agomelatine. Seven of these trials are investigating the use of agomelatine in the treatment of major disorder that is depressive. Their outcome along side the experience through the ongoing use of agomelatine in Europe may decide the future of melatonin receptor-based therapy on health improvement for U.S. patients with major depression.